下一代疗法比拼升级Infigratinib并非唯一挑战Vosoritide的选手，在ACH治疗赛道，多款下一代疗法正加速推进，从周剂注射到高选择性靶向，行业的研发比拼正不断升级，Vosoritide的垄断时代已进入倒计时。
The team have been scratching their heads trying to work out who these women were.
。关于这个话题，夫子提供了深入分析
BYOB: complexity without payoff。业内人士推荐搜狗输入法下载作为进阶阅读
elsewhere in my program.